Skip to main content
SpringerLink
Log in

Supine hypertension is longitudinally associated with verbal memory decline in Parkinson disease

  • Letter to the Editor
  • Published:
Clinical Autonomic Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

C Miller-Patterson has full access to all of the data and takes full responsibility for the integrity of the data and the accuracy of the analysis.

References

  1. Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7(1):47

    Article  PubMed  Google Scholar 

  2. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB (2015) New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72(8):863–873

    Article  PubMed  Google Scholar 

  3. Kim JS, Oh YS, Lee KS, Kim YI, Yang DW, Goldstein DS (2012) Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 79(13):1323–1331

    Article  PubMed  PubMed Central  Google Scholar 

  4. Pilotto A, Romagnolo A, Scalvini A, Masellis M, Shimo Y, Bonanni L, Camicioli R, Wang LL, Dwivedi AK, Longardner K et al (2021) Association of orthostatic hypotension with cerebral atrophy in patients with Lewy body disorders. Neurology 97(8):e814–e824

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ruiz Barrio I, Miki Y, Jaunmuktane ZT, Warner T, De Pablo-Fernandez E (2023) Association between orthostatic hypotension and dementia in patients with Parkinson disease and multiple system atrophy. Neurology 100(10):e998–e1008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W (2011) Parkinson progression marker I: the Parkinson progression marker initiative (PPMI). Prog Neurobiol 95(4):629–635

    Article  PubMed Central  Google Scholar 

  7. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356

    Article  PubMed  PubMed Central  Google Scholar 

  8. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21(2):69–72

    Article  PubMed  Google Scholar 

  9. Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, Eschlboeck S, Grassi G, Hilz MJ, Kaufmann H et al (2018) Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res 28(4):355–362

    Article  PubMed  PubMed Central  Google Scholar 

  10. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170

    Article  PubMed  Google Scholar 

  11. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653

    Article  PubMed  Google Scholar 

  12. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19(11):1306–1312

    Article  PubMed  Google Scholar 

  13. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH (2007) The REM sleep behavior disorder screening questionnaire–a new diagnostic instrument. Mov Disord 22(16):2386–2393

    Article  PubMed  Google Scholar 

  14. Vanderploeg RD, Schinka JA, Jones T, Small BJ, Graves AB, Mortimer JA (2000) Elderly norms for the Hopkins verbal learning test-revised. Clin Neuropsychol 14(3):318–324

    Article  CAS  PubMed  Google Scholar 

  15. Canavan M, O’Donnell MJ (2022) Hypertension and cognitive impairment: a review of mechanisms and key concepts. Front Neurol 13:821135

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Data used in the preparation of this article were obtained 5 October 2022 from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), Research Resource Identifier (RRID): SCR_006431. For up-to-date information on the study, check https://www.ppmi-info.org/.

Funding

The Parkinson’s Progression Markers Initiative (PPMI), a public–private partnership, is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation, and Yumanity Therapeutics.

Author information

Authors and Affiliations

  1. Department of Neurology, Virginia Commonwealth University School of Medicine, 1101 E Marshall St, Richmond, VA, 23298, USA

    Cameron Miller-Patterson, Matthew J. Barrett, Leslie J. Cloud, Brian D. Berman & Thomas C. Chelimsky

  2. Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, 423 Guardian Dr, Philadelphia, PA, 19104, USA

    Jesse Y. Hsu

Authors
  1. Cameron Miller-Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesse Y. Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew J. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leslie J. Cloud
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brian D. Berman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas C. Chelimsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cameron Miller-Patterson.

Ethics declarations

Ethics statement

Each Parkinson’s Progression Markers Initiative site received approval from an ethics committee on human experimentation in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments before study initiation and obtained written informed consent from each study participant.

Competing interests

C Miller-Patterson has received research funding from the VCU Center for Clinical and Translational Research and the National Center for Advancing Translational Sciences (ULTR002649) and serves as site PI for a clinical study funded by Ono Pharmaceutical Co, Ltd. JY Hsu has received personal compensation for serving as an editor for the National Kidney Foundation and Public Library of Science. MJ Barrett receives research funding from the U.S. NIH (R21AG077469, R21AG074368) and Kyowa Kirin, Inc, and serves as site PI for clinical trials and studies sponsored by Biogen, CHDI Foundation, Cognition Therapeutics, EIP Pharma, uniQure, Parkinson's Foundation, and Prilenia Therapeutics. LJ Cloud has been a consultant for Abbvie, has served on an advisory board and speakers bureau for Kyowa Kirin, has clinical trial contracts (paid to her institution) with Bukwang, Cerevel, UCB, and Intra-Cellular Technologies, has received honoraria from Medlink Neurology, HMP Global, M3 global research team, and Qessential research, has grants (paid to her institution) from U.S. NIH (NINDS 1R01NS120560-01), Michael J Fox Foundation, Virginia Catalyst Fund, and the Parkinson's Foundation, and has two inventions: Gastrointestinal Symptoms in Neurodegenerative Disease (GIND) scale (VCU Office of Technology Transfer # CLO-11-0R67) and Recognize and Deploy Vibration for Mitigation of Freezing of Gait (VCU Office of Technology Transfer provisional patent # PRE-21-137F (322203-8130), application filed July 2022, full patent application filed July 2023. BD Berman has received research grant support from the Dystonia Coalition (receives the majority of its support through U.S. NIH grant NS065701 from the Office of Rare Diseases Research in the National Center for Advancing Translational Science and National Institute of Neurological Disorders and Stroke), the Parkinson's Foundation, the VCU School of Medicine, the Administration for Community Living, and the Dystonia Medical Research Foundation, has received honoraria from the MedLink Corporation and the International Parkinson and Movement Disorder Society, and serves on the medical advisory board of the Benign Essential Blepharospasm Research Foundation and the National Spasmodic Torticollis Association. TC Chelimsky has received research grant support from U.S. NIH (NIDDK 5R01DK083538-08), has received personal compensation for serving as a consultant for Proctor & Gamble, and has an ownership interest in PainSTakers, LLC.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 24 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miller-Patterson, C., Hsu, J.Y., Barrett, M.J. et al. Supine hypertension is longitudinally associated with verbal memory decline in Parkinson disease. Clin Auton Res (2024). https://doi.org/10.1007/s10286-024-01026-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10286-024-01026-3

Keywords

Search

Navigation